Overweight

20 trials 1 recruiting MedDRA PT
20 Registered trials
1 Recruiting
9 Unique sponsors
12 Unique IMPs
19 Commercial trials
Drug classes (ATC)
— ATC code not specified 16
A Gastroenterology (ATC A) 4
B Haematology (ATC B) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 9 substances
GLP-1 receptor agonist 2 substances
Antiplatelet / NSAID 1 substance
Phase III: 4 Phase II: 4 Phase I/II: 1 Phase I (Other): 11

Filter these 20 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 20 trials

Phase III

4 trials
  • Amgen Inc. Commercial
    MARIDEBART CAFRAGLUTIDE
    2024-515523-11-00 6 countries 2025 n=420
    Ended
  • Amgen Inc. Commercial
    MARIDEBART CAFRAGLUTIDE
    2024-515524-36-00 8 countries 2025 n=1,060
    Ended
  • Novo Nordisk A/S Commercial
    SEMAGLUTIDE
    2022-502922-41-00 6 countries 2023 n=86
    Ended
  • Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali Academic
    ACETYLSALICYLIC ACID; CLOPIDOGREL; SEMAGLUTIDE
    2025-522486-29-01 1 country n=212
    Pending

Phase II

4 trials
  • Amgen Inc. Commercial
    MARIDEBART CAFRAGLUTIDE
    2023-510470-13-00 5 countries 2023 n=135
    Ended
  • F. Hoffmann-La Roche AG Commercial
    HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST HUMAN LATENT MYOSTATIN; TIRZEPATIDE
    2024-519561-22-00 2 countries 2025 n=78
    Ended
  • Novo Nordisk A/S Commercial
    CAGRILINTIDE; CAGRILINTIDE, SEMAGLUTIDE; SEMAGLUTIDE
    2023-505857-42-00 6 countries 2024 n=308
    Ended
  • Pfizer Inc. Commercial
    LIRAGLUTIDE; PF-07976016-87
    2024-513679-42-00 2 countries 2025 n=53
    Ended

Phase I/II

1 trial
  • AstraZeneca AB Commercial
    AZD6234; AZD9550
    2023-504215-32-00 3 countries 2023 n=108
    Ended

Phase I (Other)

11 trials
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2024-519277-18-00 1 country 2025 n=40
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2025-521401-41-00 1 country n=30
    Pending
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2025-522766-78-00 1 country 2025 n=16
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2025-524210-28-00 1 country 2026 n=10
    Ended
  • Genentech Inc. Commercial
    IMP not specified
    2025-521888-13-00 1 country 2025 n=72
    Ended
  • Genentech Inc. Commercial
    IMP not specified
    2025-521921-34-00 1 country 2025 n=32
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2024-513863-21-00 1 country n=16
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2024-518535-11-00 1 country 2025 n=8
    Ended
  • Rose Pharma Inc. Commercial
    IMP not specified
    2023-507758-34-00 1 country 2023 n=12
    Ended
  • Zealand Pharma A/S Commercial
    IMP not specified
    2024-518124-77-00 1 country 2025 n=48
    Ended
  • Zealand Pharma A/S Commercial
    IMP not specified
    2025-520598-38-00 1 country 2025 n=48
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
F. Hoffmann-La Roche AG Commercial 5 Phase I (Other), Phase II 1
Pfizer Inc. Commercial 3 Phase I (Other), Phase II 0
Amgen Inc. Commercial 3 Phase II, Phase III 0
Genentech Inc. Commercial 2 Phase I (Other) 0
Zealand Pharma A/S Commercial 2 Phase I (Other) 0
Novo Nordisk A/S Commercial 2 Phase II, Phase III 0
Rose Pharma Inc. Commercial 1 Phase I (Other) 0
AstraZeneca AB Commercial 1 Phase I/II 0
Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali Academic 1 Phase III 0
New trials by year
2023
4
2024
1
2025
11
2026
1
← All indication landscapes